Alanyl Glutamine

Summary

Alanyl Glutamine (CHEMBL3707366) is a phase-3 clinical-stage small molecule (ATC B05XB02); indicated across 2 conditions including coronary artery disorder and acute kidney injury.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: B05XB02
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 217.22 Da · C8H15N3O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707366
Name	Alanyl Glutamine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	123935
ChEBI	CHEBI:73788
ATC	B05XB02
Molecular formula	C8H15N3O4
Molecular weight	217.22
InChIKey	HJCMDXDYPOUFDY-WHFBIAKZSA-N

SMILES: C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)N

IUPAC name: (2S)-5-amino-2-[[(2S)-2-aminopropanoyl]amino]-5-oxopentanoic acid

ChEBI definition: A dipeptide formed from L-alanyl and L-glutamine residues.

Other ChEBI roles (chemical / environmental): metabolite.

Also known as: Ala-gln, Alanyl glutamine, Alanyl-glutamine dipeptide, Dipeptamin, FEMA NO. 4712, Glutamax, L-alanyl-l-glutamine, L-alanyl-l-glutamine amino acid, N(2)-l-alanyl-levoglutamide, Sustamine, ALANYL GLUTAMINE, L-ALANINE-L-GLUTAMINE

Patent coverage: 12,461 distinct patent families (29,290 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 29,289 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Amine oxidase [flavin-containing] A.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
coronary artery disorder	3	MONDO:0005010	EFO:0001645
acute kidney injury	3	MONDO:0002492	HP:0001919

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04560309	PHASE3	COMPLETED	Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF
NCT06065566	Not specified	COMPLETED	Effect of Parenteral Glutamine on Myocardial Injury and Inflammation Biomarkers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).